886363-54-8 Usage
General Description
[4-(tert-butyl-dimethyl-silanyloxymethyl)phenyl]-acetic acid is a chemical compound that belongs to the class of organosilicon compounds. It is a silane derivative containing an acetic acid functional group and a phenyl ring. The compound is used in various applications, including in the synthesis of pharmaceuticals and in the production of specialty chemicals. It is also used as a building block in organic synthesis and as a reagent in chemical reactions. Additionally, it can be used as a coating and adhesive agent, and in the manufacturing of polymers and materials with specific properties. Overall, [4-(tert-butyl-dimethyl-silanyloxymethyl)phenyl]-acetic acid has diverse uses and is a versatile compound in the chemical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 886363-54-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,6,3,6 and 3 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 886363-54:
(8*8)+(7*8)+(6*6)+(5*3)+(4*6)+(3*3)+(2*5)+(1*4)=218
218 % 10 = 8
So 886363-54-8 is a valid CAS Registry Number.
InChI:InChI=1/C15H24O3Si/c1-15(2,3)19(4,5)18-11-13-8-6-12(7-9-13)10-14(16)17/h6-9H,10-11H2,1-5H3,(H,16,17)
886363-54-8Relevant articles and documents
INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS
-
Paragraph 0022; 0106; 0119, (2020/01/08)
A novel therapeutic drug for malignant tumors, cancer stem cells, or fibrosis is obtained. A therapeutic drug for malignant tumors or cancer stem cells is used that includes at least one compound selected from the group consisting of compounds represented
Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
-
Page/Page column 32, (2017/06/02)
The invention provides in part, compounds according to Formula I: and uses thereof.
HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS
-
Page/Page column 124-125, (2009/12/27)
The present invention relates to novel heterocyclic compounds of Formulae I-III: Formula I; [Chemical Formulas should be inserted here as they appears on abstract in.pdf form.] Formula II; Formula III as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder.
